DEL-BRAX Trademark
Trademark Overview
On Tuesday, June 25, 2024, a trademark application was filed for DEL-BRAX with the United States Patent and Trademark Office. The USPTO has given the DEL-BRAX trademark a serial number of 98617274. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, April 29, 2025. This trademark is owned by Avidity Biosciences, Inc.. The DEL-BRAX trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
General Information
| Serial Number | 98617274 |
| Word Mark | DEL-BRAX |
| Filing Date | Tuesday, June 25, 2024 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, April 29, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 4, 2025 |
Trademark Statements
| Goods and Services | Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology |
| Goods and Services | Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, June 25, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, June 25, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Avidity Biosciences, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121
US |
| Party Name | Avidity Biosciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121
US |
Trademark Events
| Event Date | Event Description |
| Tuesday, June 25, 2024 | NEW APPLICATION ENTERED |
| Friday, January 17, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, January 20, 2025 | ASSIGNED TO EXAMINER |
| Thursday, February 6, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, February 6, 2025 | NON-FINAL ACTION E-MAILED |
| Thursday, February 6, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, February 7, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 26, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 4, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 4, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 29, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Friday, September 5, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, September 5, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, September 5, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, October 17, 2025 | SOU TEAS EXTENSION RECEIVED |
| Friday, October 17, 2025 | TEAS STATEMENT OF USE RECEIVED |
| Thursday, March 5, 2026 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Thursday, March 5, 2026 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Thursday, March 5, 2026 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, March 5, 2026 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, March 5, 2026 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, April 6, 2026 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, October 17, 2025 | TEAS REQUEST TO DIVIDE RECEIVED |
